Resmed has received clearance from the U.S. Food and Drug Administration (FDA) for an artificial intelligence (AI)-enabled ...

Resmed (NYSE: RMD) announced today that it received FDA clearance for its Smart Comfort personalized therapy comfort settings ...

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ...

Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. | Resmed believes ...

Resmed gains FDA's nod for Smart Comfort, an AI-driven CPAP tool boosting sleep therapy personalization and adherence.

ResMed has secured FDA clearance for its Personalized Therapy Comfort Settings (PTCS), branded as Smart Comfort - a ...

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced ...

New study confirms that engaging patients with digital self-monitoring in their treatment through myAir improves adherence ResMed today announced new European research from Price Waterhouse Coopers ...

Connected sleep devicemaker ResMed today released the AirSense 11, its latest CPAP machine iteration, which includes a host of new features to treat obstructive sleep apnea. The new machine has many ...

After Philips issued a recall in mid-June of nearly two dozen models of its continuous and noncontinuous ventilators, ResMed has eagerly stepped up to fill in the market gap left by Philips’ absence.

ResMed's impressive turnaround, driven by margin improvements, innovative products, and GLP-1 drug tailwinds, positions it for significant long-term growth and elevated returns. The company's AirSense ...